Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes.

"Duality of Interest. M.R. has received personal fees for consulting or serving on advisory boards from Astra-Zeneca, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Sanofi US, and has been supported for investigator-initiated trials by Boehringer Ingelheim, Novartis Pharma, and Nutricia/Danone. R.W. reports lecture fees from Novo Nordisk, Sanofi, and Eli Lilly and served on an advisory board for Akcea Therapeutics, Daiichi Sankyo, Sanofi, Eli Lilly, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported."

"Funding. The research of M.R. is supported in part by grants from the German Federal Ministry of Health (BMG), the Ministry of Culture and Science of the State North Rhine-Westphalia and the German Federal Ministry of Education and Research both to German Center for Diabetes Research (DZD e.V.), as well as by grants from the European Community (HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A) to the INTERCEPT-T2D consortium, EUREKA Eurostars-2 (E! 113230 DIA-PEP), German Science Foundation (CRC/SFB 1116/2 B12, RTG/GRK 2576 vivid, Project 3), Schmutzler Stiftung, and the program “Profilbildung 2020,” an initiative of the Ministry of Culture and Science of the State of North Rhine-Westphalia."